1. Home
  2. CBIO vs BYND Comparison

CBIO vs BYND Comparison

Compare CBIO & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.83

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$0.84

Market Cap

446.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
BYND
Founded
2003
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
389.7M
446.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CBIO
BYND
Price
$10.83
$0.84
Analyst Decision
Strong Buy
Sell
Analyst Count
6
7
Target Price
$27.17
$1.70
AVG Volume (30 Days)
142.5K
52.1M
Earning Date
02-23-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$290,565,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$0.50
52 Week High
$21.40
$7.69

Technical Indicators

Market Signals
Indicator
CBIO
BYND
Relative Strength Index (RSI) 37.86 37.55
Support Level $10.56 $0.90
Resistance Level $14.71 $1.02
Average True Range (ATR) 1.01 0.07
MACD -0.07 -0.00
Stochastic Oscillator 6.14 0.43

Price Performance

Historical Comparison
CBIO
BYND

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: